Related Experiment Video

Updated: May 18, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Complement dysregulation and disease: from genes and proteins to diagnostics and drugs

Santiago Rodriguez de Cordoba1, Agustin Tortajada, Claire L Harris

  • 1Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas and Centro de Investigación Biomédica en Enfermedades Raras, Ramiro de Maeztu 9, 28040 Madrid, Spain. srdecordoba@cib.csic.es

Immunobiology
|September 12, 2012
PubMed

Insights

Genetic variations in complement proteins are linked to chronic and infectious diseases. Understanding these variations and complement pathways offers new therapeutic targets and personalized medicine approaches for better patient outcomes.

Area of Science:

  • Immunology
  • Genetics
  • Pharmacology

Background:

  • Genetic variations in complement system components and regulators are increasingly associated with chronic and infectious diseases.
  • Recent advances in structural biology have elucidated the assembly, activation, and regulation of the alternative pathway C3 convertase.

Purpose of the Study:

  • To explore the pathogenic mechanisms of complement-related disorders.
  • To identify potential therapeutic targets within the complement system.
  • To emphasize the role of understanding genetic and non-genetic risk factors in stratified medicine.

Main Methods:

  • Functional characterization of complement protein variants.
  • Structural analysis of complement system components.
  • Review of existing literature on genetic associations and therapeutic strategies.

Main Results:

  • Insights into pathogenic mechanisms of complement-related disorders derived from functional and structural studies.
  • Identification of complement inhibitory therapies showing efficacy.
  • Recognition of the potential for stratified medicine through comprehensive risk factor understanding.

Conclusions:

  • Understanding complement genetics and pathways is crucial for developing targeted therapies.
  • Complement inhibitory drugs show promise in altering disease progression.
  • Stratified medicine approaches, informed by risk factors, can improve patient management through tailored treatments and diagnostics.

More Related Videos

Mapping Dysfunctional Protein-Protein Interactions in Disease09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Complementation Tests00:49

Complementation Tests

A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...